Cancer patients who responded to experimental immunotherapy can now continue treatment
NCT ID NCT05572970
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This expanded access program offers balstilimab, alone or with zalifrelimab, to cancer patients who previously received these drugs in a clinical trial and saw benefit. The goal is to allow continued treatment for those who wish to stay on therapy. Only patients who completed the earlier study and meet eligibility criteria can participate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
balstilimab (alone or with zalifrelimab)
What this could lead to
If successful, this expanded access program could allow patients who previously responded to these drugs to continue treatment, potentially maintaining disease control.
What could go wrong
This is an expanded access program, not a formal trial, so it does not prove safety or efficacy. Benefits seen in earlier studies may not persist, and side effects from immunotherapy (e.g., immune-related inflammation) remain possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arizona Oncology Associates
AVAILABLETucson, Arizona, 85711, United States
-
Hoag Gynecologic Oncology
AVAILABLENewport Beach, California, 92663, United States
-
Texas Oncology
AVAILABLEFlower Mound, Texas, 75028, United States
-
The Ohio State University Wexner Medical Center
AVAILABLEColumbus, Ohio, 43212, United States
-
University of Alabama at Birmingham
AVAILABLEBirmingham, Alabama, 35249, United States
-
University of California, San Francisco Medical Center
AVAILABLESan Francisco, California, 94158, United States
-
Women & Infants Hospital of Rhode Island
AVAILABLEProvidence, Rhode Island, 02905, United States